SIGA Technologies, Inc. SIGA
SIGA Technologies, Inc. (Nasdaq: SIGA) is an infectious disease drug developer. Its lead program, TPOXX (tecovirimat) - smallpox PEP indication (supplemental NDA), is in Pre-clinical for Smallpox post-exposure prophylaxis. Its next catalyst on record is TPOXX oral - smallpox PEP indication: Supplemental NDA submission for smallpox post-exposure prophylaxis indication (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TPOXX oral - smallpox PEP indication — Supplemental NDA submission for smallpox post-exposure prophylaxis indication (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TPOXX oral (tecovirimat) | Smallpox treatment | small molecule | Approved |
| TPOXX IV (tecovirimat) | Smallpox treatment | small molecule | Approved |
| TPOXX pediatric formulation | Smallpox treatment | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.